Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Device Maker Nipro Estimates Further Growth For FY2009

This article was originally published in PharmAsia News

Executive Summary

Japanese medical device maker Nipro's 2008 sales grew by 2.2 percent to ¥175.9 billion. The operating income increased by 8 percent to ¥14.7 billion and net profit increased by 1.7 percent to ¥4.5 billion. In the domestic market, Nipro's dialysis products, injection and intravenous injection products steadily expanded market shares. Its pharmaceutical business also contributed to growth, especially in oral tablets and dialysis medicines. For fiscal year 2009, Nipro estimates further expansion in its pharma business, due largely to growth in the generic drug market and increasing diagnostic procedure combined payment methods. Estimated 2009 sales are ¥180 billion, with ¥6 billion in net product for a 33.5 percent increase. (Click here for more - Japanese language

You may also be interested in...

QUOTED. 13 December 2019. Todd Garner

ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs.  See what the CFO said about it here.

Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne

Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.

Real-World Evidence Fails Another Test At US FDA

Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts